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5-Lipoxygenase is the first committed  enzyme in the 
leukotriene biosynthetic  pathway and is known to cat- 
alyze not only the first oxygenation of arachidonate 
to form 5(S)-hydroperoxyeicosatetraenoic acid (5(S)- 
HPETE), but also dehydration of this intermediate into 
leukotriene A, (LTA,)  by an activity termed leukotriene 
A, synthase. Inhibition of cytosolic  5-lipoxygenase pre- 
pared from human blood granulocytes with zileuton 
(100 p w )  was virtually complete, but LTA, synthase ac- 
tivity was  only inhibited by 47%. Structural character- 
ization of eicosanoids  synthesized in these preparations 
revealed an abundance of 15-lipoxygenase  metabolites 
including 15-HETE  when arachidonate was  used as sub- 
strate and 5(S),15(S)-dihydroxy-6,8,11,13(E$,Z,Z)-eico- 
satetraenoic acid  when  5(S)-HPETE  was  used as sub- 
strate. When neutrophils were prepared that contained 
less than 1% eosinophil contamination, zileuton was 
found to almost  completely inhibit all 5-lipoxygenase,  as 
well as LTA, synthase products.  Immunochemical anal- 
ysis of the  supernatants from  purified neutrophils and 
eosinophils confirmed the previous observation that 
neutrophils do  not express 15-lipoxygenase. Incubation 
of 5(S)-HPETE  with  recombinant  mammalian  15-lipoxy- 
genase resulted in the formation of g-truns-LTB, and 
6-trans-12-epi-LTB4 as LTA, products, as well as the 12- 
lipoxygenase product 5(S),lZ(S)-diHPETE.  The  mecha- 
nism of action of 154ipoxygenase acting as  an LTA, syn- 
thase is proposed to involve  removing the pro-R 
hydrogen  atom at carbon-10 of 5(S)-HPETE,  which  is 
antarafacial to the hydroperoxy  group to yield LTA,. 
Leukotrienes  are  thought  to be important lipid mediators of 
the  inflammatory process  derived  from arachidonic acid (1, 2). 
The enzyme 5-lipoxygenase is  the committed enzyme of the 
leukotriene pathway,  which catalyzes  the oxidation of arachi- 
donic acid to form 5(S)-hydroperoxyeicosatetraenoic acid ( 5 ( S ) -  
HPETE).l  This enzyme is expressed in  certain cells including 
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the human polymorphonuclear leukocyte (31, mast cell (41, 
macrophage/monocyte (5), and  the osinophil (6). This dioxygen- 
ase  has been the subject of extensive studies because of the 
biological activities of its  leukotriene  products  as well as its 
unique  properties compared to  other  enzymes which  catalyze 
the oxidation of arachidonic acid. 5-Lipoxygenase is normally 
inactive as a cytosolic enzyme, but upon  elevation of the  intra- 
cellular calcium concentration is translocated  to a membrane 
compartment (71. In consort with  another  membrane protein, 
5-lipoxygenase activating  protein (8), the  first  enzymatic  trans- 
formation of insertion of molecular oxygen into arachidonic 
acid takes place.  5-Lipoxygenase has been  purified,  sequenced, 
and cloned (91, and  detailed biochemical studies of the purified 
enzyme  from PB-3 cells (10)  revealed  that it also catalyzes  the 
second step  in  the  synthesis of leukotrienes,  namely  the enzy- 
matic  dehydration of 5(S)-HPETE to  leukotriene A, (Scheme 1). 
This  dehydration  step  or LTA, synthase  activity involves the 
stereospecific  removal of a  hydrogen atom from t h e   p r o 3  po- 
sition at C-10 of 5(S j-HPETE,  which is  identical to  the  stereo- 
chemistry of the hydrogen atom at the C-7 position in  arachi- 
donic acid that is removed to form 5(S)-HPETE (10). 
The conversion of arachidonate  into LTA, has  been  reported 
to be fairly efficient, and 5(S)-HPETE is a competitive sub- 
strate  relative  to  arachidonate,  suggesting a single  active site 
for both enzymatic  steps  in  Scheme 1 (11). However, little is 
known concerning the two-step mechanism involved in  the for- 
mation of  LTA, by 5-lipoxygenase in  regard  to  whether or not 
the  intermediate  5(S)-HPETE  is  released from the enzyme or 
merely  reoriented  within  the  active  site prior to  dehydration. 
Since the discovery that the 5-lipoxygenase possesses LTA, 
synthase activity, the  search for a separate LTA, synthase  has 
not  been  pursued vigorously. There has been  one report  that 
12-lipoxygenase isolated from porcine leukocytes does have 
LTA, synthase activity  (12). In  the course of investigating  the 
suicide inactivation of 5-lipoxygenase by arachidonic acid and 
5(S)-HPETE, we observed the presence of residual LTA, syn- 
thase activity in  the cytosol of neutrophil  preparations  (granu- 
locytes) after 5-lipoxygenase had been translocated to  the mem- 
brane compartment (13). The enzyme 15-lipoxygenase was 
present  in  this broken cell cytosol, which led to  an investigation 
of 15-lipoxygenase, its cellular source in granulocyte prepara- 
tions,  and  its  activity  as  an LTA, synthase. 
EXPERIMENTAL PROCEDURES 
Chemicals and Reagents-All chemicals used were reagent-grade 
and obtained from commerical sources except as noted. Eicosanoids 
5(S), 12~R~-dihydroxy-6,8,10,14(E,E,E,Z~-eicosatetraenoic cid; 6-trans- 
15~S~-dihydroxy-6,8,11,13(E,E,Z,Z)-eicosatetraenoic acid; 6-trans-LTB4, 
acid; 15(S)-HPETE, 15(S)-hydroperoxy-5,8,11,13(Z,Z,Z,E)-eicosa- 
12-epi-LTB,, 5~S~,12~S)-dihydroxy-6,8,10,11(E,E,E,Z)-eicosatetraenoic 
tetraenoic acid; HPLC, high pressure liquid chromatography; LT, leukotri- 
ene; LTA,, 5~S~,6~S~-trans-o~do-7,9,11,14(E,E,Z,Z)-eicosatetraenoic acid; 
LTB,, 5~~~,12~R~-dihydroxy-6,8,10,14~Z,~,E,Z~-eicosatetraenoic acid; 
LTC,, 5~S~-hydroxy-6~R)-S-glutathionyl-7,9,11,14(~,~,Z,Z)-eicosa- 
tetraenoic  acid. 
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were purchased from Cayman Chemical Co. (Ann  Arbor,  MI).  HPLC- 
grade solvents were obtained from Fisher. Zileuton  was a kind gift from 
Dr.  George Carter from  Abbott Laboratories (North Chicago, IL). Puri- 
fied human 15-lipoxygenase antibody and expression of recombinant 
15-lipoxygenase has been reported previously (14, 15). Professor 
Channa Reddy (Pennsylvania State University) provided 5(S)-HPETE 
as a product following incubation of arachidonic acid with potato 5- 
lipoxygenase (16). 
Preparation of Human Granulocytes-Venous blood was obtained 
from adult volunteers who had received no medication in  the period 1 
week prior to collection. Neutrophils and eosinophils were prepared 
using plasma Percoll gradients with techniques to  minimize exposure to 
bacterial endotoxin (17). The peripheral leukocytes  collected in  the 51- 
55% Percoll gradient will  be referred to as  the granulocyte preparation 
to indicate that  it was a mixture of cell types, primarily polymorpho- 
nuclear leukocytes (9597%)  as well as eosinophils (34%). The exact 
composition of this preparation was largely dependent upon the indi- 
vidual donor peripheral leukocyte population. Purified neutrophils 
(polymorphonuclear leukocytes) were obtained as the fraction collected 
between 5345% Percoll and typically contained less than 1% eosi- 
nophils as assessed by staining  and light microscopy. The 47-49% Per- 
coll gradients were  collected  for the pure eosinophil preparation, and 
they contained less than 1% neutrophils. Both the crude granulocyte 
and neutrophil preparations were resuspended in KRPD buffer to  a 
concentration of 7-10 x 10, celldml. Eosinophil preparations were re- 
suspended in KRPD buffer to concentrations of  1-3 x 10, celldml. Pro- 
teins were quantitated by UV spectrometry using the Pierce  bicincho- 
ninic  acid  (BCA) protein kit. 
Cell Zncubations-Cells in KRPD buffer a t  concentrations indicated 
were preincubated at 37 "C for 10 min, and  then CaCl,  (200 mM) was 
added to cell suspensions to bring the final Ca2+ concentration to 2 mM. 
Calcium  ionophoreA23187 (0.5 pl, 10 n" in Me,SO), arachidonic acid (2 
pl, 10 m~ in EtOH), or the respective solvent blanks were added to 
initiate the cell incubation. The reactions were  quenched with two  vol- 
umes of cold methanol containing 50 ng of the  internal  standard PGB, 
and  then stored on  ice. Samples were centrifuged at 4 "C for  10 min at 
1000 x g, and pellets were discarded. Acetic  acid (0.05 M, pH  5.7, ad- 
justed with NH,OH) was added to each supernatant to  give a final 
concentration of methanol less than 20%  (v/v). The supernatants were 
applied to C,, solid phase extraction columns obtained from Jones Chro- 
matography (Lakewood,  CO).  After sample application, the extraction 
columns  were  washed with 5 ml  of water. Eicosanoids  were eluted with 
2 ml of methanol and  then lyophilized. The eluants were  redissolved in 
1 ml of the  initial HPLC  mobile phase. The eicosanoids  were quanti- 
tated by a HPLC  method as described  previously (18). 
Preparation ofLysed  Cells-Unstimulated neutrophil and eosinophil 
preparations were centrifuged for 10 min at 4 "C at 55 x g. For some 
ton, 2 mM CaCl,, and 1 p~ A23187  for 30  min prior to centrifugation. The 
experiments the cell suspensions were preincubated with 100 PM zileu- 
supernatants were discarded. The cell pellets were resuspended to 2 x 
10,  cells/ml in lysis buffer (0.050 M phosphate buffer, pH  7.4, 0.100 M 
sodium  chloride, 2.0 mM EDTA, 0.1 unitdm1 aprotinine, 1 pg/ml  pep- 
statin, 1 pg/ml leupeptin) and then lysed during four 15-s bursts by using 
a Braun-Sonic 2000 sonicator at low frequency. Small aliquots of each 
sample were reserved for protein assay.  Sonication was followed  by cen- 
trifugation for 10 min at 10,000 x g  at 4 "C, and  then for  60  min at 100,000 
x g at 4 "C. The supernatant was taken as the cytosol preparation, and 
this contained the zileuton if it was added prior to stimulation. 
Assay  for  5-Lipoxygenase and LTA, Synthase-The  cytosol prepara- 
tions were diluted 10-fold  corresponding to an original concentration of 
1 x lo7 cells/ml. The standard assay mixture contained 5 ml of cytosol 
to which was added ATP (100 pl, 200 mM), egg  yolk  glycerophosphocho- 
line (100 pl, 20 mg/ml), and, for certain experiments, zileuton (5 pl, 100 
mM, in Me,SO). This assay mixture was preincubated for 2 min. After 
thermal equilibration, CaCl, (100 pl, 200 mM) and arachidonic acid (5 
pl, 15 n" in ethanol) were added to assay 5-lipoxygenase activity, 
whereas 5(S)-HPETE (5 pl, 12 m~ in ethanol) was used in  separate 
aliquots to assay for LTAa synthase activity.  After incubation at various 
times at 37 "C as indicated, the reaction was quenched with two  vol- 
umes of cold methanol and the  internal  standard PGB, (50 ng) was 
added. The assay for  5-lipoxygenase  included  5-HETE,  5-oxo-6,8,11,14- 
(E,Z,Z,Z)-eicosatetraenoic acid, and LTA, products, as well as any dual 
lipoxygenase products. The assay for LTA, synthase using 5(S)-HPETE 
as substrate is reported as LTA, products, which includes LTB,, 20- 
hydroxy-LTB,,  A6-trans-LTB,, and 12-epi-LTB,, 5,g-diHETEs (5(S),6(S)- 
and 5(S),6~~~-dihydroxy-7,9,11,14~E,E,Z,Z)-eicosatetraenoic acid), and 
LTC,. 
Gel Electrophoresis and Western  Blots-Protein samples were diluted 
1:4 in SDS reducing buffer and gel electrophoresis carried out essen- 
tially as  that described by Laemmli (19). The 15-lipoxygenase primary 
antibody (15) was incubated for 2  h at a dilution of 1:6000 with proteins 
transferred to a nitrocellulose membrane. After washing, the membrane 
was incubated with goat anti-rabbit IgG-labeled horseradish peroxidase 
(Amersham Corp.) diluted 1:lOOO. Chemiluminescence detection was 
employed using the Amersham ECL Western blotting Analysis  System. 
Hemoglobin  Oxidation-5(S)-HPETE (10 PM) was incubated for  30 
min with 1 mg  of  hemoglobin  or 2  x lo9 erythrocytes suspended in  2 ml 
of  KRPD. Reaction  was  stopped by addition of  two volumes of methanol. 
Production of LTA, metabolites was monitored by reverse phase HPLC, 
using 50 ng of  PGB, as the  internal  standard. 
15-Lipoxygenase  Metabolism of 5(S)-HPETE-Recombinant 15- 
lipoxygenase (14) (5-15 pg)  was  dissolved in 1 ml of lysis buffer con- 
taining 2 m~ ATP, 200 pg of glycerophosphocholine, and  2 mM Ca". 
Arachidonic  acid (8 pg) or 5(S)-HPETE (8 pg) was added to the solution 
after warming to 37 "C. Incubation was carried out for  20 min and  then 
terminated by addition of 50 pl of formic  acid and 50 ng of  PGB, as the 
internal standard. Two volumes of hexane/ethyl acetate (1/1) were 
added to extract eicosanoids. The organic layer was taken to dryness, 
dissolved in 1 ml of initial HPLC  mobile phase, then analyzed by  HPLC. 
For  some experiments hydroperoxides  were  reduced  to  alcohols by in- 
cubation with SnC1, (3.5 p ~ )  for  30 min prior to HPLC analysis. 
HPLC-Reverse phase HPLC was performed  on a Beckman Ultra- 
sphere 5-pm C,, column  (250 x 4.6 mm) (Beckman, Fullerton, CA). The 
initial mobile phase was a 70:30 mixture of 0.05 M acetic  acid (pH 5.7 
adjusted with NH,OH) and acetonitrile/methano1(65:35). The flow rate 
was 1 mumin. Gradient elution was carried from 3045% acetonitrile/ 
methanol over 10 min, 5540% over  25 min, and 80-100%  over 2 min. 
The retention times of synthetic eicosanoid standards relative to  the 
PGB, internal  standard were determined. 
A second  HPLC solvent system was used for  some experiments. The 
initial mobile phase was a 5545 mixture of 0.05 M acetic  acid (pH 5.7 
adjusted with NH,OH) and methanol. GraGent elution was carried 
from  55%-65% methanol over  10 min, 65%-85%  over  25 min, and 85% to 
100%  over 5 min. This system did not separate  the sulfido-leukotrienes, 
however. 
Identification of eicosanoids in each HPLC fraction was made by 
retention time, UV absorption spectra, and mass spectrometry to con- 
firm each structure. Concentrations of eicosanoid products were deter- 
mined  from their HPLC peak heights at maximum absorbance relative 
to that of  PGB, at 280  nm and calculated from the responses of standard 
compounds. 
Mass Spectrometry-Selected  HPLC fraction were  collected and ly- 
ophilized  to dryness. Aliquots of some samples were  reduced with rho- 
dium on alumina with hydrogen gas gently bubbling through the reac- 
tion mixture for 2 min (20). Pentafluorobenzyl ester derivatives were 
formed by a reaction with 10% pentafluorobenzyl bromide and 10% 
diisopropylethanolamine (both in acetone) at room temperature for 20 
min. Trimethylsilyl derivatives were generated by addition of 50 pl  each 
of bis(trimethylsily1) trifluoroacetamide and acetonitrile, and  the reac- 
tion mixture was heated to  60 "C  for 5 min and then lyophilized. 
The derivatized samples were  dissolved in acetonitrile prior to  injec- 
tion into the Finnigan-Mat SSQ70  GC/MS (San Jose, CAI. The GC was 
equipped with either a 5 or 10 m x 0.25-mm, 0.2-pm film thickness 
capillary column and heated from  150 "C to 300 "C at a rate of 15 "c/ 
min. The mass spectrometer was operated in the electron capture ion- 
ization mode using methane as moderating gas at 0.5 torr ion  source 
pressure. After molecular weight information was obtained with elec- 
tron capture ionization, additional material was subjected to electron 
impact ionization as a means to determine structure. 
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TABLE 1 
Activity of 5-lipoxygenase  and  LTA,  synthase in  100,000 X g 
supernatant  preparation of unstimulated  human  granulocytes 
in the presence and absence of 100 p~ zileuton 
5-Lipoxygenase products represent sum of 5-HPETE, 5-HETE, 5-oxo- 
ETE, LTB,, and nonenzymatic products of  LTA, hydrolysis  derived  from 
arachidonate as substrate. LTA, synthase products correspond to LTB, 
and LTA, nonenzymatic products derived  from  5-HPETE as substrate. 
5-Lipoxygenase LTA, synthase 
ng  eicosanoids I ng LTA, products I 
pg  protein pg  protein 
Supernatant 7.0 f 1.4" 2.2 f 0.2 
Supernatant and zileuton NDb 1.2 f 0.1 
S.E., n = 3. 
Not detected. 
RESULTS 
Cell-free Incubations-Investigation of the enzymatic  activ- 
ity  retained  in  the 100,000 x g supernatant from granulocyte 
preparations (cytosol) was  carried  out  using arachidonic acid 
(15 w) and  5(S)-HPETE (15 VM) to  measure, respectively, 5- 
lipoxygenase and LTA, synthase activity as previously reported 
(10, 13, 18). As seen in Table I, 5-lipoxygenase activity was 
present  in  the cytosol fraction and  was completely inhibited by 
100 w zileuton, a reversible 5-lipoxygenase inhibitor (211, but 
significant LTA, synthase activity was still detected in the 
granulocyte supernatant when  zileuton was  present.  The  study 
of dose-dependent inhibition of 5-lipoxygenase or LTA, syn- 
thase activities in granulocyte supernatants (Fig. 1) by zileuton 
suggested  that LTA, synthesis could occur independent of 5- 
lipoxygenase in  this  preparation. At  a  concentration of 100 p ~ ,  
zileuton completely inhibited 5-lipoxygenase activity as ex- 
pected but only inhibited LTA, synthase activity by 47%. 
The  data suggested that  an  alternative  pathway for LTA, 
synthesis  was  present  in  the granulocyte cytosol (or that zileu- 
ton only inhibited one of the two activities of 5-lipoxygenase). 
Studies  have  demonstrated  that ydroperoxides such  as 15(S)- 
HPETE  and  5(S)-HPETE  can be converted to dihydroxyeicos- 
anoids via epoxides such as 14,15-LTA4 and LTA, through  the 
actions of hemeproteins (22, 23). In  these  studies,  transforma- 
tion of hydroperoxides to  the diols was 0.1-2% of added  sub- 
strate. However, in  our  studies, conversion of 5(S)-HPETE  to 
LTA, products by the 5-lipoxygenase-independent LTA, syn- 
thase  was 6-12%  of added  substrate.  In  addition, incubation of 
5(S)-HPETE  with 1 mg of hemoglobin produced less  than 1%  of 
diol eicosanoids, and incubation with erythrocytes failed to 
yield any detectable quantities of  LTA, products (data not 
shown). I t  is unlikely, therefore, that  the 5-lipoxygenase-inde- 
pendent LTA, synthase activity reported  here  was  due  to non- 
enzymatic conversion of 5(S)-HPETE by hemeproteins  present 
in leukocytes or erythrocytes contaminating the granulocyte 
preparations. 
5(S)-HPETE Metabolism by Granulocytes-Incubation of 
arachidonic acid with the cytosol preparation from resting 
granulocytes in  the  assay for 5-lipoxygenase yielded the typical 
products shown in Fig. 2A corresponding to LTB, and the 
6-trans-LTB4  isomers from nonenzymatic  hydrolysis of  LTA,. A 
small  amount of the 5,6-diHETEs  also was a product of LTA, 
hydrolysis that  eluted between  35 and  37 min. In  this  prepa- 
ration, which was typical for most  granulocyte preparations, a 
component eluting from the HPLC at 42 min  was identified by 
its HPLC retention  time as well as gas chromatographic be- 
havior as 15-HETE. This  substance  eluted prior to the expected 
major lipoxygenase product, 5-HETE, which eluted after 45 
min  in  this HPLC run. 
Incubation of resting granulocytes with 15 VM 5(S)-HPETE 
yielded 5-HETE (not shown in Fig. 2), LTA, products (LTB,, 
6-trans-LTB4, and 6-trans-12-epi-LTB4), 5(S),12(S)-diHETE, 
S-Lipoxygeme Activity 
0.0 
0 " .01 . I  1 10 100 low 
Zileuton ( uM) 
FIG. 1. Dose-dependent  inhibition of 5-lipoxygenase  and LTA, 
synthase  activity by zileuton in granulocyte  cytosol  prepara- 
tions. 5-Lipoxygenase activity was measured using arachidonic acid 
(15 p) as substrate  and LTA, activity using 5(S)-HPETE (15 m) as 
substrate. Experiments were camed out in triplicate and results  are 
expressed as the mean S.E. 
5-Lipoxygenase LTAq Synthase 
-w 6-CLTB4 P 2 3 a 235 nm 2 70 nm 1 IS-HETE 
235 nm 
270 nm 
10 20 30 40 
5SJZS-diHETE 
235 nm 
D. 100m Ziloulon I(l5-diHETE 
5S.12S-diHETE 
.,- 2 7 0  nm 
1 1 1 1 1 1 l  
10 20 30 40 
Time (min) 
FIG. 2. HPLC separation  of  5-lipoxygenase  and LTA, synthase 
products  present  following  incubation  of  human  granulocyte 
cytosol with arachidonic acid and 5(S)-HPETE, respectively. 
Conjugated diene products were detected at 235 nm and conjugated 
triene metabolites and the internal  standard (PGB,,  50 ng) were de- 
tected at 270  nm. A, products obtained from granulocyte cytosol incu- 
bated with arachidonic acid (15 p). B, products obtained following 
incubation of granulocyte cytosol preparation containing zileuton (100 
PM) and arachidonic acid (15 p). C ,  products obtained from incubation 
of granulocyte cytosol preparation with 5(S)-HPETE (15 p). D, prod- 
ucts obtained from incubation of granulocyte cytosol preparation con- 
taining zileuton (100 p) and 5(S)-HPETE (15 w). 
and  an unexpected  major  metabolite eluting  with a retention 
time of 27 min (Fig. 2 B ) .  Its U V  spectrum  had a maximum 
absorbance at 245 nm consistent with a cross-conjugated diene 
chromophore. The  mass  spectrum of this metabolite  revealed  a 
molecular weight of 336 daltons from the pentafluorobenzyl, 
trimethylsilyl  electron capture  mass  spectrum with a carboxyl- 
ate  anion at mlz 479. The  retention  time  and all physical data 
were consistent  with  this product as 5,E-diHETE (24).  Syn- 
thesis of 5,15-diHETEs  from the added 5(S)-HPETE was not 
suppressed upon addition of 100 zileuton (Fig. 2 0 ) .  
Eosinophil  Contribution-Preparations of neutrophils 
(granulocytes) from peripheral blood are  usually  contaminated 
with 3-5% eosinophils. Selection of the two lowest bands of the 
Percoll separation  gradient  during cell isolation minimized the 
eosinophil population in the neutrophil preparations to less 
than 1%. When these  neutrophils were lysed in  the presence of 
100 PM zileuton, then  the cytosol incubated with  5(S)-HPETE, 
HPLC analysis revealed nearly 5 times  less LTA, products than 
observed when  the cytosol from eosinophils treated  in  an iden- 
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as assessed by incubation of 5(S)-HPETE with  purified cell cy- 
FIG. 3. HPLC separation of products of LTA, synthase activity 
tosol preparations. A, cytosol from neutrophils that contain less 
than 1% contaminating eosinophils incubated with 5(S)-HPETE (15 
p ~ )  in the presence of zileuton (100 p ~ ) .  B ,  cytosol  from  eosinophils in- 
cubated with 5(S)-HPETE (15 p) in the presence of zileuton (100 p). 
An unknown metabolite (unk) was detected that had a W absorption 
maximum at 315  nm. This metabolite was only present in  the eosino- 
phil experiments. PGB, was added as internal  standard (50 ng). Prod- 
ucts were identified by  HPLC retention time and W absorption 
characteristics. 
tical manner were  analyzed  (Fig. 3). Incubation of relatively 
pure eosinophil cytosol preparations containing  less than 1% 
neutrophils with 5(S)-HPETE  and zileuton resulted  in  several 
triene eicosanoids including 6-trans-LTB,, 6-trans-12 epi-LTB,, 
LTB,, and  5(S),12(S)-diHETE  as  seen from the HPLC profile at 
270 nm (Fig.  3B). There  was sufficient 5,E-diHETE produced 
that  it  was  detected at 270 nm even though it had a X,, at 245 
nm.  The unknown component (unk  in Fig. 3B) was present  in 
the eosinophil preparation  without zileuton (data  not shown). 
The cytosol preparation from granulocytes, purified eosin- 
ophils or neutrophils (containing less than 1% eosinophils) 
were  subjected to SDS-polyacrylamide gel electrophoresis and 
probed with anti-human 15-lipoxygenase (15). The Western 
blot revealed that 15-lipoxygenase did occur in  normal  prepa- 
rations of granulocytes. Equal  amounts of protein from mixed 
cell granulocyte and purified neutrophil  preparations exhibited 
significant 15-lipoxygenase only in  the mixed cell preparations. 
In a comparison of eosinophils and purified neutrophils (Fig. 41, 
15-lipoxygenase appeared much more abundantly  in  the eosin- 
ophil lanes,  although  these  lanes  were loaded with protein from 
10-100 times fewer cells. 
Incubation of 5(S)-HPETE  with recombinant 15-lipoxygen- 
ase yielded several  products  including the expected 5,E-dihy- 
droperoxyeicosatetraenoic acid (Fig. 5). This dihydroperoxy ei- 
cosanoid has not been previously reported, likely because 
cellular peroxidases that rapidly degrade such hydroperoxy 
groups to  the dihydroxy metabolite were not present  in  this 
incubation  system. This metabolite  did have  the  characteristic 
UV absorption maximum at 245 nm for a cross-conjugated 
chromophore. Three products were identified as conjugated 
triene eicosanoids based  upon the  characteristic UV absorption 
maximum at 270 nm. Two of the conjugated eicosanoids eluted 
from the HPLC column at the exact retention  time for 6-trans- 
LTB, and 6-truns-epi-LTB4 between 14.5 and 15 min. Further- 
more, these 15-lipoxygenase metabolites  were characterized by 
mass spectrometry to correspond to  5,12-dihydroxyeicosatet- 
raenoic acid based  upon gas chromatography/mass  spectrome- 
try. Thus,  these products  reveal the production of the  triene 
epoxide LTA, as an enzymatic product of 5(S)-HPETE and 
15-lipoxygenase. 
The  third major product of 15-lipoxygenase metabolism of 
5(S)-HPETE contained a conjugated triene chromophore, as 
evidenced by its UV absorption spectra which maximized at 
270 nm. This  metabolite eluted from the HPLC substantially 
later  than  that expected for LTB, (15.5 min)  in a region where 
no other known leukotriene or dihydroxyeicosatetraenoic acid 
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FIG. 5. HPLC separation of the products  obtained  following 
(14). 15-Lipoxygenase (130 pmol)  was incubated for 20 min at 37 "C 
with 5(S)-HPETE (15 p ~ ) .  The HPLC effluent was  monitored at 235  nm 
(A) and 270 nm ( B ) .  The LTA, products correspond  to  6-trans-LTB, and 
6-truns-12-epi-LTB4 were structurally characterized using ultraviolet 
spectroscopy, coelution with standards,  and mass spectrometric tech- 
niques. An unexpected  major metabolite 5(S),12(S)-dihydroperoxy- 
6,8,10,14 (E,E,Z,Z,)-eicosatetraenoic acid had the characteristic UV 
chromophore at 270 nm and following the reduction with SnCl,  was 
converted to the dihydroxy compound and coeluted with a synthetic 
standard  and  had identical mass spectrometric behavior. 
had been observed. The metabolite could not be converted into 
a volatile  derivative for GC/MS analysis  using  standard proto- 
cols, but  required prior  reduction  with SnC1,. Following reduc- 
tion, the HPLC retention  time of the metabolite (still  retaining 
the conjugated triene chromophore) eluted exactly at  the posi- 
tion expected for 5(S),12(S)-diHETE. Mass  spectrometric anal- 
ysis (GCiMS) showed that  the methyl ester, trimethylsilyl ether 
derivative  behaved in an identical manner to  a standard 
5(S),12(S)-diHETE derivative with a prominent saddle indi- 
cating  thermal decomposition on the  gas chromatographic col- 
umn (25). This  metabolite yielded a carboxylate anion at mlz 
479 under electron capture ionization conditions indicating  this 
metabolite was a dihydroxyeicosatetraenoic acid. Catalytic re- 
duction of the molecule followed  by electron  ionization of the 
pentafluorobenzyl ester trimethylsilyl ether derivative yielded 
abundant ions a t  mlz 173,311 (401-go), 369, and 507 (597-90) 
corresponding to a-cleavage to trimethylsiloxy  groups at carbon 
atoms 5 and 12. 
DISCUSSION 
The discovery that 5-lipoxygenase had  dual enzymatic  activi- 
ties capable of synthesizing  5(S)-HPETE  as well as dehydrat- 
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ing  this  intermediate  into LTA,, focused most attention on 5- 
lipoxygenase as  the LTA, synthase  within granulocyte prepa- 
rations. However, our experiments  with zileuton to  inhibit spe- 
cifically 5-lipoxygenase activity suggested the presence of a 
second source of  LTA, synthase activity in  these  preparations. 
This  alternate source of activity, unlike 5-lipoxygenase, was  not 
inhibited by zileuton and did not  translocate  to  the  membrane 
following cell activation (13). 
Clues  to  the  identity of the possible second LTA, synthase 
were first obtained from an  HPLC analysis of granulocyte cy- 
tosol preparations, which had been incubated  with arachidonic 
acid or 5(S)-HPETE  in  the presence or absence of zileuton. 
Products of LTA, metabolism were observed from both sub- 
strates,  but zileuton  only partially  inhibited formation of  LTA, 
from 5(S)-HPETE while completely inhibiting conversion of 
arachidonic  acid into LTA,. Products of 15-lipoxygenase activ- 
ity (15-HETE and  5,E-diHETE) were also present. Zileuton 
inhibited 5-lipoxygenase (ED,, 9 VM), but did not  inhibit  the 
15-lipoxygenase activity even at 100 VM. Based on the previous 
observations  that soybean 15-lipoxygenase (26)  and RBL-1 cell 
12-lipoxygenase (12) had catalytic activity that would dehy- 
drate hydroperoxy intermediates  in a mechanism  identical  to 
LTA, synthase, we considered that 15-lipoxygenase in our 
preparations of granulocytes might serve as an alternative 
LTA, synthase. 
Eosinophils are known to  express 15-lipoxygenase (24, 27, 
281, but  the presence of 15-lipoxygenase in  neutrophils  has been 
a subject of some controversy in  the  literature.  For example, 
Vanderhoek and Bailey (29) suggested an  increased 15-lipoxy- 
genase activity in  neutrophils challenged with ibuprofen. This 
was  later found by Fitzpatrick  and co-workers (30)  to be due  to 
lysis of cells by the  high  concentrations of ibuprofen employed 
in  the  neutrophil  preparation  rather  than a direct effect of ibu- 
profen. Sigal and co-workers purified (31) and cloned (15) hu- 
man 15-lipoxygenase; however, they  reported  not  finding  the 
enzyme or its  message  in  neutrophils (32). Morita et al. (28) 
found that highly  purified neutrophil  preparations  containing 
less  than 1% eosinophils produced negligible 15-HETE when 
compared to production of 15-HETE by eosinophil preparations. 
Using  an antibody  directed against 15-lipoxygenase to probe 
typical preparations of granulocytes  clearly indicated  the pres- 
ence of 15-lipoxygenase in  the isolated cell supernatant (cy- 
tosol). Since  eosinophils are known to  constitute 3-5% of the 
cells present  in typical  granulocyte preparations,  the  question 
was  whether or not the  small  amount of eosinophils present  in 
these  preparations could be the source of this 15-lipoxygenase. 
The cytosol of neutrophil  preparations  that contained less  than 
1% eosinophil contamination were analyzed for the presence of 
15-lipoxygenase protein and found to contain markedly re- 
duced amounts compared to  cruder  preparations of granulo- 
cytes. Furthermore,  the cytosol obtained  from  purified eosino- 
phil preparations similarly tested revealed substantial 15- 
lipoxygenase expression detected by immunoblot. When the 
purified neutrophil or eosinophil preparations were treated 
with  5(S)-HPETE  in  the presence of zileuton, only the eosino- 
phil preparation yielded abundant LTA, and 15-lipoxygenase 
products. The purified neutrophil  preparation produced no 15- 
HETE or other 15-lipoxygenase metabolites  in  agreement  with 
previous  work (281, and LTA, products were almost completely 
suppressed by the 5-lipoxygenase inhibitor. Thus, our bio- 
chemical data as well as immunochemical data confirmed that 
15-lipoxygenase is not expressed by the  neutrophil,  but  rather 
is present  in  the eosinophil. 
The  question of whether or not 15-lipoxygenase was respon- 
sible for the observed LTA, synthase activity in  the granulocyte 
preparations  was  still an  open issue. Interestingly, Vliegent- 
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of dehydration of 15(S)-HPETE by 15-lipoxygenase that  leads  to  the 
FIG. 6. LTA, synthase  activity of 15-lipoxygenase. A, mechanism 
formation of 14,15-LTA4 as  suggested by experiments from Brash  and 
co-workers (24). B, LTA, synthase  activity of 15-lipoxygenase  where the 
substrate  5(S)-HPETE  is  oriented  in  the  active  site,  which  places  the 
C-10 p r o 3  proton in  an  antarafacial position  to  the  hydroperoxy  group 
C-5. This  orientation  and  the  carbon  atoms f 5(S)-HPETE  are  identical 
to  those of 15(S)-HPETE  except at   C-I,  C-18, and C-20. 
hart  and co-workers suggested that  the bovine neutrophil 12- 
lipoxygenase (33) and RBL 12-lipoxygenase (12)  possessed 
LTA, synthase activity. Certain 12-lipoxygenases are known to 
display 15-lipoxygenase activity as evidenced by 15-HETE for- 
mation following incubation of arachidonic  acid with  this  puri- 
fied enzyme (12, 34, 35). The  similarities  between 15- and 12- 
lipoxygenase activities  are not surprising since the  enzymes 
share a great  deal of primary  amino acid sequence identity. 
Human reticulocyte 15-lipoxygenase has 86% sequence homol- 
ogy with porcine leukocyte 12-lipoxygenase (361, but only  66% 
sequence homology with  human  erythroleukemia 12-lipoxygen- 
ase (36), an  enzyme that does not express  detectable 15-lipoxy- 
genase activity (34). The striking observation that a single 
amino acid substitution  in 12- or 15-lipoxygenase from differ- 
ent origins can induce 15- or 12-lipoxygenase activity, respec- 
tively  (37, 38), was  further evidence of the  similarity between 
these two enzyme  families. Thus, it appeared likely that  the 
LTA, synthase activity exhibited by bovine neutrophil 12-li- 
poxygenase could be mimicked by human 15-lipoxygenase. This 
was directly demonstrated by our experiments  with recombi- 
nant 15-lipoxygenase incubated  with  5(S)-HPETE. 
When  arachidonic  acid is held at the active site of 15-lipoxy- 
genase, hydrogen is  abstracted from the  carbon at position 13, 
followed by covalent attachment of oxygen at the C-15 position 
to yield 15(S)-HPETE. This same enzyme can catalyze the 
dehydration reaction where  the pro-R proton at C-10 of 15(S)- 
HPETE is abstracted  in a position antarafacial  to  the ydroper- 
oxy moiety at C-15 in  the  transition state for concerted forma- 
tion of 14,15-LTA4. This mechanism has been supported by 
elegant  labeling  studies by Brash  and co-workers (24). If 5(S)- 
HPETE  is placed in  such  an active site of 15-lipoxygenase, but 
inverted  relative  to that  described for 15(S)-HPETE,  the pro-R 
proton at C-10 (of 5(S)-HPETE) is now in the antarafacial 
position to  the hydroperoxy group at C-5 (Fig. 6). I t  is this 
26668 Eosinophil  15-Lipoxygenase Is a  Leukotriene A, Synthase 
proton that  is removed by LTA, synthase (10). Furthermore, 
the  intervening double bonds (A6truns, Ascis in  5(S)-HPETE, 
and A13trans,  Allcis in  15(S)-HPETE) between the hydroperoxy 
group and  the labile  proton are  in identical relative configura- 
tions. In  fact,  the  structural  unit of 15(S)-HPETE from C-2 
through C-18 is superimposible with  the  structural  unit C-18 
through C-2 of 5(S)-HPETE (Fig. 6). Dehydration of the hy- 
droperoxide in  5(S)-HPETE  leads  to formation of  LTA,, analo- 
gous to  the previous  mechanism  described for the formation of 
14,15-LTA4. Both LTA, and 14,15-LTA4 metabolites are ob- 
served  when eosinophils are  stimulated  with  the calcium iono- 
phore A23187 and arachidonic acid. This suggests  that both 
mechanisms are operational in  the  intact eosinophil. Further- 
more, the  results from intact cell stimulation  suggest  that 5(S)- 
HPETE from eosinophil 5-lipoxygenase has  ready access to  the 
eosinophil 15-lipoxygenase for conversion into LTA,. Another 
metabolite synthesized by eosinophil 15-lipoxygenase as well 
as recombinant 15-lipoxygenase was 5(S),12(S)-diHETE. This 
metabolite has been thought to be a unique eicosanoid reflect- 
ing dual lipoxygenation by 5-lipoxygenase and 12-lipoxygen- 
ase,  but  our  results suggest that its synthesis may, in  part, be 
due  to  the action of 15-lipoxygenase and 5-lipoxygenase. 
The  results of these  experiments suggest that  the eosinophil 
has a redundant enzyme for the formation of LTA, from 5(S)- 
HPETE. The eosinophil yields a different spectrum of eico- 
sanoids relative to other granulocytes following appropriate 
activation. Stimulation of the  neutrophil  leads  to production of 
LTB,, the potent chemotactic factor which is probably respon- 
sible for recruitment of neutrophils  to  sites of infection and 
inflammation (1). The eosinophil opens additional enzymatic 
pathways for LTA, metabolism and produces not only LTB,, but 
also LTC,, which has  the properties previously ascribed to slow 
reacting  substance of anaphylaxis (4). 
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